Protalix BioTherapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $52.7M | $53.4M | $65.5M | $47.6M | $38.4M |
| Cost of revenue | $27.0M | $24.3M | $23.0M | $19.6M | $16.3M |
| Selling, general & administrative | $11.7M | $12.2M | $15.0M | $11.7M | $12.7M |
| Research and development | $19.6M | $13.0M | $17.1M | $29.3M | $29.7M |
| Operating income | -$5.5M | $3.9M | $10.5M | -$13.0M | -$20.5M |
| Pretax income | -$5.6M | $4.2M | $8.6M | -$14.4M | -$27.6M |
| Income tax expense | $996,000 | $1.2M | $254,000 | $530,000 | — |
| Net income | -$6.6M | $2.9M | $8.3M | -$14.9M | -$27.6M |
| Balance Sheet | |||||
| Cash and equivalents | $14.7M | $19.8M | $23.6M | $17.1M | $39.0M |
| Current assets | $66.7M | $60.1M | $69.9M | $44.9M | $61.7M |
| Total assets | $82.3M | $73.4M | $84.4M | $55.8M | $73.7M |
| Current liabilities | $26.5M | $25.6M | $45.5M | $32.4M | $33.2M |
| Total liabilities | $34.1M | $30.2M | $50.9M | $66.4M | $79.7M |
| Stockholders' equity | $48.2M | $43.2M | $33.6M | -$10.6M | -$6.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$12.0M | $8.7M | -$1.3M | -$25.0M | -$10.3M |
| Depreciation and amortization | $1.5M | $1.3M | $1.2M | $1.1M | $1.1M |
| Stock-based compensation | $2.3M | $3.3M | $3.4M | $2.1M | $2.4M |
| Capital expenditure | $1.6M | $1.3M | $1.1M | $628,000 | $1.5M |
| Free cash flow | -$13.6M | $7.4M | -$2.5M | -$25.6M | -$11.7M |
Shares outstanding 80.6M · Free float 85.1%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.